Drug intelligence / Profile preview

allogenic adipose tissue-derived mesenchymal progenitor cells

Development stage: Unknown
Lead developer: AbelZeta, Inc.
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

Allogenic adipose tissue-derived mesenchymal progenitor cells are a type of cell therapy developed by Shanghai AbelZeta Ltd. for the treatment of Knee Osteoarthritis. These cells are administered via intra-articular injection and are believed to exert their therapeutic effects through regenerative and immunomodulatory properties, aiming to repair damaged tissue and reduce inflammation in the affected joint.

Brand names: AlloJoin
Other names: Mesenchymal progenitor cells

Beyond the preview

Go deeper on allogenic adipose tissue-derived mesenchymal progenitor cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on allogenic adipose tissue-derived mesenchymal progenitor cells.

Explore the full profile